Novartis ADR Forecast, price target & analysts
Novartis ADR Target price 2025 - Analyst rating & recommendation
Novartis ADR Classifications & Recommendation:
Novartis ADR Price Target
| Target Price | $115.87 |
| Price | $112.26 |
| Potential |
3.21%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target Novartis ADR 2026 .
The average Novartis ADR target price is $115.87.
This is
3.21%
register free of charge
$139.14
23.95%
register free of charge
$89.77
20.03%
register free of charge
|
|
| A rating was issued by 28 analysts: 5 Analysts recommend Novartis ADR to buy, 19 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Novartis ADR stock has an average upside potential 2026 of
3.21%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 50.32 | 53.08 |
| 10.73% | 5.49% | |
| EBITDA Margin | 42.40% | 40.44% |
| 4.36% | 4.62% | |
| Net Margin | 23.24% | 24.63% |
| 25.23% | 5.99% |
20 Analysts have issued a sales forecast Novartis ADR 2025 . The average Novartis ADR sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Novartis ADR EBITDA forecast 2025. The average Novartis ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Novartis ADR Analysts have issued a net profit forecast 2025. The average Novartis ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 5.92 | 6.62 |
| 17.20% | 11.82% | |
| P/E | 16.96 | |
| EV/Sales | 4.35 |
13 Analysts have issued a Novartis ADR forecast for earnings per share. The average Novartis ADR EPS is
This results in the following potential growth metrics and future valuations:
Current Novartis ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
| BNP PARIBAS EXANE |
Locked
➜
Locked
|
Locked | Jan 05 2025 |
| DAY BY DAY |
Locked
➜
Locked
|
Locked | Jan 05 2025 |
| GUGGENHEIM SECURITIES LLC |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| TD COWEN |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
| HSBC |
Locked
➜
Locked
|
Locked | Nov 24 2024 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Nov 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jan 06 2025 |
|
Locked
BNP PARIBAS EXANE:
Locked
➜
Locked
|
Jan 05 2025 |
|
Locked
DAY BY DAY:
Locked
➜
Locked
|
Jan 05 2025 |
|
Locked
GUGGENHEIM SECURITIES LLC:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
TD COWEN:
Locked
➜
Locked
|
Dec 10 2024 |
|
Locked
HSBC:
Locked
➜
Locked
|
Nov 24 2024 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Nov 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
